References
- Kanavos P, Vandoros S, Irwin R, Nicod E, Casson M. Differences in Costs of and Access to Pharmaceutical Products in the EU. European Parliament Report, DG Internal Policies. Policy Department, Economic and Scientific Committee A, Brussels, Belgium (2011).
- Lopez-Casasnovas G, Puig-Junoy J. Review of the literature on reference pricing. Health Policy54, 87–123 (2000).
- Towse A. If it ain’t broke, don’t price fix it: the OFT and the PPRS. Health Economics16(7), 653–665 (2007).
- Berger PL, Luckmann T. The Social Construction of Reality. Anchor Books, NY, USA (1966).
- Meyer JW, Rowan B. Institutionalized organisations: formal structures as myth and ceremony. Am. J. Sociol.83, 340–363 (1977).
- Robson K, Humphrey C, Khalifa R, Jones J. Transforming audit technologies: business risk audit methodologies and the audit field. Account. Organizations Soc.32(4–5), 409–438 (2007).
- Healy PM, Wahlen JM. A review of the earnings management literature and its implications for standard setting. Account. Horizons13, 365–383 (1999).
- Shah SZA, Yuan H, Zafar N. Earnings management and dividend policy an empirical comparison between Pakistani listed companies and Chinese listed companies. Int. Res. J. Finance Econ.35, 51–60 (2010).
- Cahan S. The effect of antitrust investigations on discretionary accruals: a refined test of the political cost hypothesis. Account. Rev.67, 77–95 (1992).
- Jones JJ. Earnings management during import relief investigations. J. Account. Res.29, 193–228 (1991).
- Key KG. Political cost incentives for earnings management in the cable television industry. J. Account. Econ.23(3), 309–337 (1997).
- Shah AK. Creative compliance in financial reporting. Account. Organizations Soc.21(1), 23–29 (1996).
- Coffee JC. Gatekeepers: The Professions and Corporate Governance. Oxford University Press, Oxford, UK (2006).
- Bodner DA, Rouse WB, Pennock MJ. Using simulation to analyze R&D value creation. In: Proceedings of the 2005 Winter Simulation Conference. Kuhl ME, Steiger NM, Armstrong FB, Joines JA (Eds). 1906–1913 (2005).
- Dechow PM, Sloan RG. Executive incentives and the horizon problem: an empirical investigation. J. Account. Econ.14, 51–89 (1991).
- Baber WR, Fairfield PM, Haggard JA. The effect of concern about reported income on discretionary spending decisions: the case of research and development. Account. Rev.66, 818–829 (1991).
- Bushee BJ. The influence of institutional investors on myopic R&D investment behavior. Account. Rev.73, 305–333 (1998).
- Cheng S. R&D expenditures and CEO compensation. Account. Rev.79, 305–328 (2004).
- Oswald DR, Zarowin P. Capitalization of R&D and the informativeness of stock prices. Eur. Account. Rev.16(4), 703–726 (2007).
- Griffiths I. Creative Accounting. Unwin Paperbacks, London, UK (1987).
- Jackson SB, Pitman MK. Auditors and earnings management. CPA J.71(7), 38–44 (2001).
- Bennett S, Quick JD, Velasquez G. Public–private roles in the pharmaceutical sector – implications for equitable access and rational drug use. Health Economics and Drugs Series, No. 005. WHO, Geneva, Switzerland (1997).
- Weyman-Jones T. Regulation prices and profits. In: International Handbook on Privatisation. Saal DS, Parker D (Eds). Edward Elgar, Cheltenham, UK (2003).
- Averch H, Johnson L. Behavior of the firm under regulatory constraint. Am. Econ. Rev.52(5), 1052–1070 (1962).
- Department of Health. The Pharmaceutical Price Regulation Scheme: Tenth Report to Parliament. Central Office of Information for the Department of Health, London, UK (2009).
- Kanavos P, Vandoros S. Determinants of branded prescription medicine prices in OECD countries. Health Econ. Policy Law6(3), 313–335 (2011).
- Danzon PM, Chao L-W. Cross national price differences for pharmaceuticals: how large and why? J. Health Econ.19, 159–195 (2000).
- Danzon PM, Furukawa MF. Prices and availability of pharmaceuticals: evidence from nine countries. Health Aff.W3-521–W3-536 (2003).
- Kanavos P, Vandoros S. Drugs US: are prices too high? Measuring international pharmaceutical price differences. Significance8(1), 15–18 (2011).
- Grover R. Curtains for tinsel town accounting? Business Week 14 January, 35 (1991).
- Thornton S. Drug price reform in the UK: debunking the myths. Health Econ.16(10), 981–992 (2007).
- Kanavos P, Manning J, Taylor D, Schurer W, Checci K. Implementing Value-Based Pricing for Pharmaceuticals in the UK. 2020health, London, UK (2010).
- Towse A. Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right wrong? Br. J. Clin. Pharmacol.70(3), 360–366 (2010).
- Claxton K. OFT, VBP: QED? Health Econ.16(6), 545–558 (2007).
Websites
- The UK Pharmaceutical Price Regulation Scheme (PPRS). Department of Health. www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_098498.pdf (Accessed 2 June 2010)
- Office of Fair Trading. The Pharmaceutical Price Regulation Scheme – Annexe H (Profit Controls) (2007). www.oft.gov.uk/shared_oft/reports/comp_policy/oft885.pdf (Accessed 16 June 2010)
- Office of Fair Trading. The Pharmaceutical Price Regulation Scheme. London (2007). www.oft.gov.uk/shared_oft/reports/comp_policy/oft885.pdf (Accessed 16 June 2010)
- Alexander I, Irwin T. Price Caps, Rate-of-Return Regulation, and the Cost of Capital. World Bank. www.worldbank.org/html/fpd/notes/notelist.html (Accessed 6 February 2010)
- Rapp RT, Lloyd A. ‘Civilized’ Pharmaceutical Price Regulations: Can The U.S. Have It Too? National Economic Research Associates. www.cato.org/pubs/regulation/regv17n2/reg17n2-rapp.html (Accessed 22 November 2009)